Author of

• 11692

  +

  P2.10 - Poster Session 2 - Chemotherapy (ID 207)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 11741

    +

    P2.10-049 - Lung and Bone Metastasis Are Associated With Different Response and Disease Control Rate of First-line Therapy in Patients With Adenocarcinoma of Lung. (ID 3164)

    09:30 - 09:30  |  Author(s): C. Wu
    • Abstract

    Background
    Bone and lung are frequent metastatic sites for adenocarcinoma of lung. Chemotherapy and tyrosine-kinase inhibitor (TKI) are standard first-line therapies for stage IV adenocarcinoma of lung according to the epidermal growth factor receptor (EGFR) mutation status. This study aimed at evaluating the relationship between bone, lung metastasis, with or without classic EGFR mutation, response rate and disease control rate of first-line chemotherapy and TKI therapy.

    Methods
    We retrospectively reviewed 206 patients who were diagnosed of adenocarcinoma of lung at our hospital. The patients’ bone and lung metastatic status at diagnosis, with or without classic EGFR mutation, response and disease control status of first-line chemotherapy and TKI therapy were collected for chi-square analysis.

    Results
    Fifty-five (26.7%) patients had bone metastasis and 82 (39.8%) patients had lung metastasis. 107 (51.9%) patients had classic EGFR mutation. There was no significant difference between bone, lung metastatic status and with or without classic EGFR mutation (p=0.65 for bone, p=0.46 for lung). For the patients without classic EGFR mutation and received first-line chemotherapy, 33(57.9%) patients were without response (13, 20 patients were without, with bone metastasis, respectively), 24(42.1%) patients were with response (21, 3 patients were without, with bone metastasis, respectively), p<0.01; 21(36.8%) patients were not controlled (9, 12 patients were without, with bone metastasis, respectively),36 (63.2%) patients were controlled (25, 11 patients were without, with bone metastasis, respectively), p=0.048. For the patients with classic EGFR mutation and received first-line chemotherapy, 27(60%) patients were without response (14, 13 patients were without, with bone metastasis, respectively), 18(40%) patients were with response (16, 2 patients were without, with bone metastasis, respectively), p=0.01; 10(22.2%) patients were not controlled (4, 6 patients were without, with bone metastasis, respectively), 35(77.8%) patients were controlled (26, 9 patients were without, with bone metastasis, respectively), p=0.043. There were no significant difference between response status of TKI and lung metastatic status (p=0.469), control status of TKI and lung metastatic status(p=0.855), response status of TKI and bone metastatic status(p=0.673), control status of TKI and bone metastatic status(p=0.58), response status of chemotherapy and bone metastatic status(p=0.533), control status of chemotherapy and bone metastatic status(p=0.777) in patients without classic EGFR mutation. For patients with classic EGFR mutation, there were also no significant difference between response status of TKI and lung metastatic status(p=0.077), control status of TKI and lung metastatic status(p=0.332), response status of TKI and bone metastatic status(p=0.76), control status of TKI and bone metastatic status(p=0.05), response status of chemotherapy and bone metastatic status (p=0.143), except for control status of chemotherapy and bone metastatic status(p=0.017).

    Conclusion
    For patients with adenocarcinoma of lung, bone metastasis is associated with decreased disease control rate in those with classic EGFR mutation and received first-line chemotherapy, and lung metastasis is associated with decreased response and disease control rate in those received first-line TKI therapy no matter of with or without classic EGFR mutation.